Tirzepatide outperforms Semaglutide in controlling Blood Sugar and Weight Loss in Type 2 Diabetes

A new meta-analysis of 22 studies, presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany, shows that tirzepatide is superior to semaglutide in terms of both blood sugar control and weight loss for patients with type 2 diabetes.

Semaglutide is approved for the treatment of type 2 diabetes and obesity/weight loss management, while tirzepatide has been approved for type 2 diabetes and has pending applications for obesity/weight loss management. The study combined data from 22 trials to compare the efficacy and safety of tirzepatide and semaglutide in people with type 2 diabetes.

The meta-analysis found that tirzepatide was more effective than semaglutide in reducing HbA1c (a measure of blood sugar control) across different doses. Tirzepatide also led to greater weight loss compared to semaglutide.

Some of the key findings were as follows:

Tirzepatide 15 mg was the most effective in reducing HbA1c.

Tirzepatide doses were more effective than semaglutide doses in reducing HbA1c.

Tirzepatide led to greater weight loss than semaglutide, with higher doses of tirzepatide being more effective.

For specific weight loss comparisons,

Tirzepatide 15 mg resulted in a mean weight loss of 5.72 kg more than semaglutide 2.0 mg.

Tirzepatide 10 mg resulted in a mean weight loss of 3.52 kg more than semaglutide 2.0 mg.

Tirzepatide 5 mg resulted in a mean weight loss of 1.72 kg more than semaglutide 1.0 mg.

Reference: Diabetologia

Meeting: Annual Meeting of the European Association for the Study of Diabetes (EASD)